A phase III win for the company’s uterine fibroids candidate fails to calm investor concerns about an expensive launch and a rival with deeper pockets.
Fibrogen tumbles on a confusing safety update for its most advanced project.
Astrazeneca has made another push into artificial intelligence, but admits that it will be some time before it knows whether the technology has helped its drug discovery…
May looks to be a fairly quiet month for US drug approvals, though Novartis's gene therapy should make headlines.
Transvaginal mesh implants are banned in the US, but remain a possibility in Europe.
Johnson & Johnson’s Invokana has fallen behind SGLT2 rivals over amputation fears, but success in the Credence renal trial, profiled at the International Society of…
For Urovant, beating placebo in a pivotal trial of vibegron was the easy part.
Six months after floating, Urovant is gearing up to release pivotal data on its most advanced overactive bladder project.
As the final cohort in the Phoenix trial reads out positively for bardoxolone the stage is set for pivotal results and a decision by Abbvie.